Relypsa Gains 8% On Competitor's FDA Rejection
May 27, 2016 at 20:56 PM EDT
Although the day's news regarding the hyperkalemia drug was good for Relypsa, AZN escaped the day relatively unscathed due to good news for two of its other drugs.
